Hospitalization and Emergency Department Utilization in Patients With Advanced Melanoma Receiving Pembrolizumab vs. Ipilimumab Plus Nivolumab in US Academic Centers
Journal of Medical Economics - United Kingdom
doi 10.1080/13696998.2019.1696349
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 9, 2019
Authors
Publisher
Informa UK Limited